NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis $11.26 -0.35 (-2.97%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About DBV Technologies Stock (NASDAQ:DBVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DBV Technologies alerts:Sign Up Key Stats Today's Range$11.00▼$11.5550-Day Range$7.74▼$11.5452-Week Range$2.20▼$12.78Volume16,520 shsAverage Volume191,172 shsMarket Capitalization$308.27 millionP/E RatioN/ADividend YieldN/APrice Target$14.75Consensus RatingModerate Buy Company Overview DBV Technologies is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy solutions for food and environmental allergies. At the core of its research is the Viaskin® platform, an epicutaneous patch technology designed to deliver micro-doses of allergen through intact skin to elicit desensitization while minimizing systemic exposure. The company’s lead program, Viaskin Peanut, is being evaluated in pivotal Phase III trials in both the United States and Europe, offering a novel approach to addressing one of the most common and potentially severe food allergies in children and adults. Beyond its peanut allergy program, DBV Technologies is advancing additional Viaskin immunotherapies targeting cow’s milk allergy, atopic dermatitis associated with food allergies, and other allergens such as hen’s egg and cat dander. These programs are at various stages of clinical development, highlighting the platform’s versatility and the company’s commitment to addressing unmet medical needs in allergy care. DBV collaborates with leading academic institutions and regulatory authorities to design and execute trials that meet rigorous safety and efficacy standards. Founded in 2002 and headquartered in Bagneux, France, DBV Technologies also maintains a presence in Marlborough, Massachusetts, to support its North American operations. The company was co-founded by renowned allergists and scientists, and its leadership team is headed by CEO Marco Zannoni, whose experience spans global product development and regulatory strategy. DBV’s scientific advisory board comprises experts in allergy and immunology, reinforcing its strategic vision to transform the treatment landscape for allergic diseases worldwide.AI Generated. May Contain Errors. Read More DBV Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreDBVT MarketRank™: DBV Technologies scored higher than 74% of companies evaluated by MarketBeat, and ranked 248th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDBV Technologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DBV Technologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($7.05) to ($5.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 7.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DBV Technologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.08% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.08% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.79 News SentimentDBV Technologies has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for DBV Technologies this week, compared to 2 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $730.00 in company stock.Percentage Held by InsidersOnly 1.44% of the stock of DBV Technologies is held by insiders.Percentage Held by Institutions71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DBV Technologies' insider trading history. Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DBVT Stock News HeadlinesDBV Technologies S.A. (DBVT) - Yahoo FinanceJuly 4 at 12:59 AM | finance.yahoo.comDBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 2, 2025 | americanbankingnews.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 7 at 2:00 AM | Crypto 101 Media (Ad)Analysts Issue Forecasts for DBVT Q2 EarningsJuly 1, 2025 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Upgraded at Lifesci CapitalJune 29, 2025 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Given Market Outperform Rating at JMP SecuritiesJune 27, 2025 | americanbankingnews.comDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old - MorningstarJune 26, 2025 | morningstar.comMDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years OldJune 26, 2025 | uk.finance.yahoo.comSee More Headlines DBVT Stock Analysis - Frequently Asked Questions How have DBVT shares performed this year? DBV Technologies' stock was trading at $3.09 at the beginning of the year. Since then, DBVT stock has increased by 264.2% and is now trading at $11.2550. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) released its quarterly earnings data on Friday, April, 11th. The company reported ($1.10) EPS for the quarter. The company earned $0.51 million during the quarter. DBV Technologies had a negative trailing twelve-month return on equity of 278.24% and a negative net margin of 3,249.99%. When did DBV Technologies' stock split? DBV Technologies shares reverse split on the morning of Friday, November 29th 2024.The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings4/11/2025Today7/07/2025Next Earnings (Estimated)7/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DBVT CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$14.75 High Stock Price Target$21.00 Low Stock Price Target$7.25 Potential Upside/Downside+27.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($4.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.92 million Net Margins-3,249.99% Pretax Margin-3,249.79% Return on Equity-278.24% Return on Assets-140.54% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual Sales$4.15 million Price / Sales76.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book8.13Miscellaneous Outstanding Shares27,390,000Free Float26,996,000Market Cap$316.05 million OptionableOptionable Beta-0.59 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:DBVT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.